🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This #SleepAwarenessWeek, we thank the entire sleep community for their work in helping to increase awareness of sleep-wake disorders. To learn more, listen to Hypersomnia Foundation's upcoming webinar on March 14th. beyondsleepywebinar.funraise.org.

Today, Centessa announced business highlights and financial results for Q4 and the Full-Year 2024. Read the full release for more details: investors.centessa.com/news-releases/…

Today, Centessa presented data from the Phase 1 trial of our most advanced OX2R agonist at the American Academy of Neurology 2025 Annual Meeting. This asset is being investigated in an ongoing Phase 2 trial for sleep-wake disorders. Access the poster here: investors.centessa.com/static-files/5… #AANAM

The 2025 American Academy of Neurology Annual Meeting Exhibit Hall is now open. Visit us at Booth #627 to learn more about our potential best-in-class OX2R agonist franchise. The Hall opens daily at 11:30 a.m. PT. See you there! #AANAM

Thank you Hypersomnia Fdn for featuring Deborah Hartman, PhD, Centessa's Global Scientific Head of the Orexin Program, in the 'Living With…' series. Watch the episode below. #ThisisH #ForTheSleepyOnes #HypersomniaAwareness #IdiopathicHypersomnia #SleepDisorder #FakeAwake

We were excited to welcome our colleagues from across the pond and around the U.S. to our Boston office. This marks the first time in 2025 that we were all under the same roof, bringing opportunities for important conversation, collaboration, and a little fun!

We recently announced the recipients of our Innovation Award - two colleagues who embrace the values of Centessa. We thank Satish Girirajan and Jun Hu for their hard work and for being outstanding colleagues.

Congratulations Emmanuel Mignot, MD, PhD and Chair of our SAB for being presented with his 2023 Breakthrough in Life Sciences for discovering the role of orexin in narcolepsy and paving the way for potential new treatments for sleep-wake disorders. youtube.com/watch?app=desk…

Started the morning right at Wake Up Narcolepsy 's 2025 National Summit. Proud to sponsor this important event offering an interesting mix of individual speakers, panels and support groups for those affected by narcolepsy and IH. If you are in Raleigh, stop by our table and say hi!

We're still thinking about the amazing people we met Wake Up Narcolepsy 's 2025 National Summit over the weekend. The annual event sparks meaningful dialogue while promoting general awareness of narcolepsy and IH. We are proud to have sponsored this event. centessa.com/orexin-agonist….

This morning, $CNTA announced business highlights and financial results for Q1. See a brief summary below, with the full release available on our website at: investors.centessa.com/news-releases/…

In June, members of Centessa’s management team will participate in fireside chats at Jefferies and Goldman Sachs. Conference details are in our PR: investors.centessa.com/news-releases/…

Centessa is at the Jefferies Global Healthcare Conference today. #JefferiesHealthcare

Centessa team members just touched down in Seattle to kick off a busy and exciting week ahead! First up: the #BeyondSleepy Conference with Hypersomnia Fdn, then onto SLEEP 2025 with American Academy of Sleep Medicine and Sleep Research Society.

Today is Idiopathic Hypersomnia Day, and we are proud to show our support for #IH patients and the IH community. Together, we are #MoreThanIH! Info about the @HypersomniaNew’s initiative here: hypersomniafoundation.org/ihday/

Another great year at the #BeyondSleepy Conference. As always, the Hypersomnia Fdn has put together an incredible event of leading experts in narcolepsy and IH, for which we are proud sponsors. Wonderful to see so many familiar faces and make new connections!

Today, we are presenting at #SLEEP2025, hosted by American Academy of Sleep Medicine & Sleep Research Society. Featuring previously shared Ph 1 data of our novel OX2R agonist & Ph 2a CRYSTAL-1 trial design in patients with NT1, NT2 & IH. Our posters can be found on our website following SLEEP.

That’s a wrap on #SLEEP2025! Thank you to American Academy of Sleep Medicine and Sleep Research Society for bringing together the sleep medicine and research community to share insights, connect, and explore the future of sleep science, including orexin agonists.

We’re excited to announce FDA clearance of our IND to initiate a Phase 1 trial of ORX142, the second OX2R agonist in our orexin franchise. The Phase 1 study is expected to begin imminently, with clinical data anticipated later this year. Read more: investors.centessa.com/news-releases/…